Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
Rhea-AI Summary
Jupiter Neurosciences (NASDAQ:JUNS) has begun enrolling patients in its Phase 2a RESET trial of oral candidate JOTROL™ for Parkinson’s disease. The 30-patient, 12-week, randomized, double-blind, placebo-controlled study focuses on safety, tolerability and pharmacokinetics, with secondary biomarker endpoints.
According to Jupiter Neurosciences, JOTROL™ showed ~9-fold higher plasma bioavailability versus conventional resveratrol, measurable CSF levels, and no serious adverse events in a 24‑subject Phase 1 study. An FDA IND was cleared in November 2025. Parkinson’s disease affects 1.1 million U.S. patients, with a 2024 global treatment market of $5.65 billion.
Positive
- Phase 2a RESET trial enrollment underway for JOTROL™ in Parkinson’s disease
- FDA IND cleared in November 2025, enabling Phase 2a clinical evaluation
- ~9-fold higher plasma bioavailability vs conventional resveratrol in Phase 1 (Cmax 455 vs 85 ng/mL)
- Measurable CSF JOTROL™ levels observed in Phase 1, supporting CNS exposure
- No serious adverse events reported in completed 24-subject Phase 1 study
- Global Parkinson’s treatment market projected to grow from $5.65B (2024) to $7.58B (2030)
Negative
- JOTROL™ remains an investigational drug not approved by the FDA or other authorities
- Current clinical evaluation involves a 30-patient, 12-week Phase 2a study
- RESET study completion is projected for H1 2027, delaying availability of full data
News Market Reaction – JUNS
In the May 27 session, JUNS gained 4.30%, reflecting a moderate positive market reaction. Argus tracked a peak move of +23.4% during that session. Argus tracked a trough of -10.6% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Registered direct closing | Negative | -3.3% | Closed ~$2M registered direct offering of 7,142,858 common shares. |
| May 21 | Offering closing | Negative | -12.2% | Announced closing of $2.0M registered direct offering to fund programs. |
| May 20 | Offering pricing | Negative | +10.3% | Priced $2.0M registered direct offering of 7,142,858 common shares. |
| May 20 | Licensing term sheet | Positive | +10.3% | Signed $100M term sheet for exclusive U.S. rights to ALA‑002. |
| May 04 | Investor conference | Neutral | +3.3% | Planned presentation at Market Movers Investor Summit for investors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent JUNS news often tied to financings and licensing. Offerings have usually led to negative price reactions, while the ALA-002 licensing term sheet coincided with a positive move. The market presentation also saw a modest uptick, suggesting investors respond better to strategic or pipeline expansion updates than to capital raises.
Over the past month, JUNS issued multiple financing and strategic updates. A May 20 non-binding term sheet for exclusive U.S. rights to ALA‑002 and its related offering pricing both coincided with a +10.25% move. Subsequent registered direct offering closings around $2.0M on May 21 and May 26 saw declines of −12.19% and −3.28%, respectively. An investor summit appearance on May 4 aligned with a modest +3.33% gain. Today’s Phase 2a enrollment milestone fits into a narrative of advancing JOTROL™ while managing capital needs and licensing expansion.
Key Terms
phase 2a medical
cns medical
pharmacokinetics medical
biomarkers medical
csf medical
randomized, double-blind, placebo-controlled medical
cagr financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Investigational Oral Candidate JOTROL™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available
Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that patient enrollment is now underway in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL™ (investigational trans-resveratrol micellar formulation) in Parkinson’s Disease (PD), with first patient dosing expected in the near term.
Parkinson’s Disease affects an estimated 1.1 million people in the United States, with roughly 90,000 new diagnoses annually, and carries an estimated annual U.S. economic burden of
“Despite advances in symptomatic management, there remains a significant unmet need for therapies that may address the underlying biological drivers of Parkinson’s disease. We believe JOTROL™’s enhanced CNS exposure and mechanistic profile position it as a potentially differentiated therapeutic candidate for neurodegenerative disorders characterized by oxidative stress, mitochondrial dysfunction and chronic neuroinflammation.”
— Charbel Moussa, MBBS, PhD, Professor of Neurology and Director of the Translational Therapeutics Program, Georgetown University Medical Center; Coordinating Principal Investigator, RESET Study
“The global Parkinson’s Disease treatment market — currently valued at
— Christer Rosén, Chief Executive Officer, Jupiter Neurosciences, Inc. (NASDAQ: JUNS)
"The initiation of enrolment in the Phase 2a RESET trial marks the culmination of 10 years of research and development at Jupiter and is our largest clinical milestone to date. I echo the enthusiasm of my colleagues, thank all our collaborators contributing to this accomplishment and look forward to reporting out data as the trial progresses.”
— Alison Silva, President & Chief Business Officer, Jupiter Neurosciences, Inc. (NASDAQ: JUNS)
Clinical Trial Details
Jupiter’s RESET (RESvEraTrol in Parkinson’s Disease) is active on www.clinicaltrials.gov, details here:
Study Details | NCT07592767 | RESvEraTrol in Parkinson's Disease (RESET) | ClinicalTrials.gov. The trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study designed to evaluate the JOTROL™ in Parkinson’s Disease. In a well-established model of Parkinson’s Disease JOTROL™ demonstrated statistically significant neuroprotective effects including rotarod performance and grip strength, indicating preservation of motor function. These data supported the IND granted to the Company in November 2025. A summary of key milestones and observations:
- Enrollment underway — Phase 2a RESET trial (NCT07592767) actively enrolling;
- FDA IND Cleared — November 2025, enabling commencement of Phase 2a clinical evaluation (administrative clearance only; does not imply approvability)
- ~9-fold higher overall plasma bioavailability vs. conventional resveratrol (Cmax 455 ng/mL vs. 85 ng/mL in Phase 1, n=24 healthy volunteers) https://clinicaltrials.gov/study/NCT04668274
- Measurable CSF drug levels observed in Phase 1, supporting CNS exposure
Moussa, C., et al. (2022). CNS bioavailability of JOTROL™. Journal of Alzheimer’s Disease, 88(3), 1015–1028. https://doi.org/10.3233/JAD-220211
- No serious adverse events in completed Phase 1 study (n=24 healthy volunteers)
https://clinicaltrials.gov/study/NCT04668274
- 3 study centers — Georgetown University MedStar Hospital (DC), Montgomery and Franklin Square Hospitals (MD), MedStar McLean Clinic (VA)
The RESET trial design as referenced on clinicaltrials.gov is summarized here:
| Parameter | Detail |
| Sponsor | Georgetown University / Jupiter Neurosciences / MedStar Health |
| Enrollment | 30 patients (1:1:1 randomization: two doses vs. placebo) |
| Duration | 12 weeks |
| Study Period | Enrollment underway; projected study completion H1 2027 |
| Primary Endpoints | Safety, tolerability, pharmacokinetics (plasma & CSF) |
| Secondary Endpoints | ATP blood levels, inflammatory biomarkers (blood & CSF) |
| Eligibility | PD per UK Brain Bank criteria, H&Y Stage 2–3, age 55–85, MoCA ≥18, stable on levodopa/DA agonists ≥4 weeks |
About Parkinson’s Disease Market
- 1.1 million U.S. patients living with Parkinson’s Disease https://www.parkinson.org/understanding-parkinsons/statistics
- 90,000 new U.S. diagnoses annually; 1.2 million U.S. patients projected by 2030 https://www.parkinson.org/understanding-parkinsons/statistics
$82.2 billion annual U.S. economic burden of Parkinson’s Disease https://www.parkinson.org/understanding-parkinsons/statistics- ~
90% of PD patients are Medicare-enrolled https://data.cms.gov/summary-statistics-on-beneficiary-enrollment - No disease-modifying therapies currently approved for PD; multiple investigational candidates are in active development by other companies https://www.accessdata.fda.gov/scripts/cder/daf
- Global PD treatment market:
$5.65B (2024) →$7.58B (2030), CAGR5.04% https://www.grandviewresearch.com/industry-analysis/parkinsons-disease-drugs-market - Global prevalence: >10 million patients https://doi.org/10.1016/S1474-4422(18)30295-3
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL™ -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia™, a consumer longevity supplement.
The Company has recently entered into a term sheet to acquire ALA-002 from PharmAla Biotech, a next-generation, patented psychedelic NCE. The closing of this transaction would further strengthen the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, without limitation, statements regarding patient enrolment and dosing timelines for the Phase 2a RESET trial; expected study completion dates; the proposed acquisition of exclusive U.S. licensing rights to ALA-002 from PharmAla Biotech Holdings Inc., which remains subject to due diligence, definitive agreements, regulatory approvals, and other customary closing conditions; expected development timelines; and potential regulatory pathways. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, that clinical trials may not demonstrate adequate safety or tolerability; enrolment may be slower than anticipated; preliminary data may not be predictive of future results; the proposed ALA-002 transaction may not be consummated on the expected timeline or at all; and other risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 filed on April 1, 2026. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements. We assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.com
Media Contact
Josh Birch, Media Relations Manager
KNB Communications
JBirch@KNBComm.com
